ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

EAH Eco Animal Health Group Plc

85.50
1.50 (1.79%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Eco Animal Health Group Plc LSE:EAH London Ordinary Share GB0032036807 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  1.50 1.79% 85.50 83.00 88.00 85.50 84.00 84.00 186,890 14:13:21
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Chem,fertlizer Minrl Mng,nec 85.31M 1.01M 0.0149 57.38 57.92M

ECO Animal Health Regulatory Approval

02/04/2019 7:00am

UK Regulatory


Eco Animal Health (LSE:EAH)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Eco Animal Health Charts.
 
TIDMEAH 
 
 

2 April 2019

 

ECO Animal Health Group plc

 

(AIM: EAH)

 

ECO RECEIVES EUROPEAN MARKETING AUTHORISATION FOR AIVLOSIN® FOR BREEDING CHICKENS

 

ECO Animal Health Group plc (the "Group") is pleased to announce that its subsidiary ECO Animal Health Limited (ECO) has received a marketing authorisation from the European Medicines Agency (EMA) for the use of Aivlosin® 625 mg/g Water Soluble Granules (WSG) in breeding chickens.

 

This approval allows ECO to market Aivlosin® 625 mg/g WSG in Europe for the treatment and metaphylaxis of respiratory infections caused by Mycoplasma gallisepticum in breeding chickens producing eggs, for hatching broiler stock and for replacement layers.

 

Aivlosin®, ECO's patented antimicrobial, is used under veterinary prescription for the treatment of a variety of economically important respiratory and enteric (gut) diseases in poultry and pigs.

 

Marc Loomes, CEO, commented: "The EU has five per cent of the world's layer and ten per cent of the world's broiler parent stock. This marketing authorisation is very significant as it provides an opportunity to roll out the approval beyond the EU into the multi-million dollar large international poultry markets. This will enable ECO to capitalise on the considerable global potential for Aivlosin® which offers a safe and highly effective medication for Mycoplasma infections in high value breeding birds".

 

The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR").Upon the publication of this announcement via a Regulatory Information Service ("RIS"), this inside information is now considered to be in the public domain.

 

Contacts:

 

ECO Animal Health Group plc

 
Marc Loomes                                       020 8447 6906 
Spiro Financial 
Anthony Spiro                                     020 8336 6196 
IFC Advisory Ltd                                  0203 934 6630 
Graham Herring, Miles Nolan 
N+1 Singer (Nominated Adviser and Joint Broker)   020 7496 3000 
Mark Taylor, James White, Brough Ransom 
Peel Hunt LLP (Joint Broker) 
James Steel, Dr Christopher Golden                020 7418 8900 
 
 

ECO Animal Health Group plc is a leader in the development, registration and marketing of pharmaceutical products for animals. Our products for these global growth markets promote well-being. Our financial goals are achieved through the careful and responsible application of science to generate value for our shareholders

 
 
 

View source version on businesswire.com: https://www.businesswire.com/news/home/20190401005683/en/

 
This information is provided by Business Wire 
 
 

(END) Dow Jones Newswires

April 02, 2019 02:00 ET (06:00 GMT)

1 Year Eco Animal Health Chart

1 Year Eco Animal Health Chart

1 Month Eco Animal Health Chart

1 Month Eco Animal Health Chart

Your Recent History

Delayed Upgrade Clock